



Not actual patient.

Getting started with JELMYTO

Your partner in treating low-grade
upper tract urothelial cancer

Approved Use for JELMYTO

JELMYTO[®] is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC).

Important Safety Information

You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.

Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you

- are pregnant or plan to become pregnant. JELMYTO can harm your unborn baby. You should not become pregnant during treatment with JELMYTO. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.

Please see Important Safety Information throughout and [click here](#) for JELMYTO Full Prescribing Information, including the Patient Information.

Proven to help eliminate tumors in low-grade upper tract urothelial cancer

The results from the OLYMPUS study showed that:

58% of participants had their tumors disappear after treatment with JELMYTO*

*Results achieved when JELMYTO was given once a week for 6 weeks to 71 participants.



At 1 year, 56% of the patients who had their tumors disappear were still tumor free

Important Safety Information (cont'd)

Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you (cont'd)

Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO and for 6 months after the last dose.

Males being treated with JELMYTO: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO and for 3 months after the last dose.

- are breastfeeding or plan to breastfeed. It is not known if JELMYTO passes into your breast milk. Do not breastfeed during treatment with JELMYTO and for 1 week after the last dose.
- Tell your healthcare provider if you take water pills (diuretic).

Please see Important Safety Information throughout and [click here](#) for JELMYTO Full Prescribing Information, including the Patient Information.


Jelmyto[®]
(mitomycin) for pyelocalyceal solution

What to expect BEFORE treatment



- Your doctor will tell you to take a medicine called **sodium bicarbonate** before each JELMYTO treatment. Your doctor will provide instructions about how to take this
- Be sure to tell your doctor if you take **water pills (diuretic)**
- You and your doctor may decide that general anesthesia is right for you, but **general anesthesia is not required** with JELMYTO

Be sure to tell your doctor about your medical conditions and all the medications you take

Important Safety Information (cont'd)

How will I receive JELMYTO?

- Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO treatment.
- You will receive your JELMYTO dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses.
- JELMYTO is given to your kidney through a tube called a catheter.
- During treatment with JELMYTO, your healthcare provider may tell you to take additional medicines or change how you take your current medicines.

After receiving JELMYTO:

- JELMYTO may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours.

Please see Important Safety Information throughout and [click here](#) for JELMYTO Full Prescribing Information, including the Patient Information.


Jelmyto[®]
(mitomycin) for pyelocalyceal solution

What to expect DURING treatment



- Your doctor will give you JELMYTO through a thin flexible tube called a catheter or a nephrostomy tube once weekly for 6 weeks



- JELMYTO treatment is given at a clinic, hospital, or ambulatory surgery center, and you generally don't have to stay overnight

It's important to keep all of your appointments. But if you do miss an appointment, call your doctor right away to reschedule

Important Safety Information (cont'd)

After receiving JELMYTO (cont'd):

- To urinate, **males and females should sit** on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water.
- Clothing that comes in contact with urine should be washed right away and washed separately from other clothing.

JELMYTO may cause serious side effects, including:

- **Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction).** If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO.
- **Bone marrow problems.** JELMYTO can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO. Your healthcare provider may need to temporarily or permanently stop JELMYTO if you develop bone marrow problems during treatment with JELMYTO.

Please see Important Safety Information throughout and [click here](#) for JELMYTO Full Prescribing Information, including the Patient Information.


Jelmyto[®]
(mitomycin) for pyelocalyceal solution

What to expect **AFTER** treatment



- While this is not the case for everyone, JELMYTO may cause your urine to turn a violet to blue color after treatment. Your urine flow should otherwise be normal
- JELMYTO contains chemotherapy that is still active when you urinate after treatment

Take precautions when you urinate:


- Avoid contact with urine for at least 6 hours after treatment
- Male and female patients both should sit on a toilet, and flush the toilet several times after use
- Wash your hands, inner thighs, and groin with soap and water after urination
- Wash your clothing right away if any urine gets on it, and separately from your other clothing

Important Safety Information (cont'd)

The most common side effects of JELMYTO include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please see Important Safety Information throughout and [click here](#) for JELMYTO Full Prescribing Information, including the Patient Information.



Possible side effects with JELMYTO

Contact your doctor's office right away if you develop any of the side effects below or if they worsen.


Serious side effects may include:

- **Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction):** Your doctor may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. This will help you urinate and protect your kidney. Tell your doctor right away if you develop side pain or fever during treatment.
- **Bone marrow problems:** JELMYTO can affect your bone marrow and may cause a decrease in white blood cell, red blood cell, and platelet counts. Your doctor will do blood tests before each treatment.

The most common side effects of JELMYTO in clinical trials were:

- Urinary tract infection
- Blood in your urine
- Side pain
- Nausea
- Trouble with urination
- Kidney problems
- Vomiting
- Tiredness
- Stomach (abdomen) pain

Please see Important Safety Information throughout and [click here](#) for JELMYTO Full Prescribing Information, including the Patient Information.



What to know if you are sexually active



For women:

- Do not become pregnant during treatment with JELMYTO. If you become pregnant, contact your doctor immediately
- You should use effective birth control during treatment with JELMYTO and for 6 months after the last dose
- Do not breastfeed during treatment with JELMYTO



For men:

- If you have a female partner who may become pregnant, use effective birth control during treatment with JELMYTO and for 3 months after the last dose

Ask your doctor about effective methods of preventing pregnancy during treatment with JELMYTO

Please see Important Safety Information throughout and [click here](#) for JELMYTO Full Prescribing Information, including the Patient Information.


Jelmyto[®]
(mitomycin) for pyelocalyceal solution

JELMYTO is a different kind of chemotherapy for low-grade upper tract urothelial cancer



Given directly into your kidney to help eliminate low-grade tumors*



Once-weekly dosing for 6 weeks



Typically sent home the same day

Scan for more information about JELMYTO



*Results achieved when JELMYTO was given once a week for 6 weeks to 71 participants.

Not actual patient.

Approved Use for JELMYTO

JELMYTO[®] is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC).

Important Safety Information

You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.

Please see Important Safety Information throughout and [click here](#) for JELMYTO Full Prescribing Information, including the Patient Information.



JELMYTO[®] and UroGen[®] are registered trademarks of UroGen Pharma, Ltd.
© 2024 UroGen Pharma, Inc. All rights reserved. US-JEL-00919 04/24

